Dbv technologies provides updates on the viaskin peanut program in children and toddlers and reports second quarter and half-year 2024 financial results

ChÂtillon, france, july 30, 2024 dbv technologies provides updates on the viaskin peanut program in children and toddlers and reports second quarter and half-year 2024 financial results vitesse enrollment in peanut allergic 4-7-year-olds is on-track and recruitment is expected to be complete by end of q3 2024 dbv submitted a labeling proposal, informed by the epitope efficacy data, to the food and drug administration (fda) to address the fda's protocol queries regarding patch wear-time in comfort toddlers dbv closes q2 2024 with a cash balance of $66.2 million; due to cost-saving measures, the company's cash runway is extended into q1 2025 dbv technologies (euronext: dbv – isin: fr0010417345 – nasdaq stock market: dbvt), a clinical-stage biopharmaceutical company, today shared an update on the phase 3 study, vitesse ( v iaskin peanut i mmunotherapy t rial to e valuate s afety, s implicity and e fficacy), using the modified viaskin peanut patch, in children ages 4 – 7 years old with peanut allergy. the company also provided a status update on the comfort (characterization of the optimal management of food allergy relief and treatment) toddlers supplemental safety study in 1 – 3-year-olds with peanut allergy.
DBVT Ratings Summary
DBVT Quant Ranking